Manufacturers report positive results for difamilast for atopic dermatitis

In two Phase III Japanese studies (one in adults, and one in paediatrics), manufacturers report that the portion of patients whose global assessment of disease scores were clear, or almost clear was superior for this phosphodiesterase 4 inhibitor vs placebo.


Biospace Inc.